VE-822 ATR Inhibitor: Selective DNA Damage Response Blockade in Pancreatic Cancer Research

Executive Summary: VE-822 is a potent, selective ATR inhibitor (IC₅₀ = 0.019 μM) that disrupts the ATR signaling pathway central to the DNA damage response (DDR), leading to marked radiosensitization of pancreatic ductal adenocarcinoma (PDAC) cells in preclinical models (https://www.apexbt.com/ve-822.html). VE-822 increases persistent DNA damage and reduces homologous recombination repair, particularly in cancer cells with p53 and K-Ras mutations (Zhen et al., 2023, DOI). When combined with gemcitabine and radiation, VE-822 prolongs tumor growth delay in vivo without increasing normal tissue toxicity. The compound is highly soluble in DMSO (≥50 mg/mL), but not in water or ethanol, and requires proper storage and handling to maintain activity. APExBIO supplies VE-822 as SKU B1383 for research use only, supporting advanced mechanistic DDR studies and translational PDAC research.

Biological Rationale

The ATR (ATM-Rad3-Related) kinase is a master regulator of the cellular response to DNA replication stress and double-strand breaks (DSBs). ATR activation ensures S and G2/M phase cell cycle checkpoints and coordinates homologous recombination repair, maintaining genome stability in both normal and malignant cells (Zhen et al., 2023). Many tumors, especially PDAC, harbor mutations in p53 and K-Ras that render them highly dependent on ATR signaling for survival under genotoxic stress. Inhibiting ATR selectively sensitizes these tumor cells to DNA-damaging agents, sparing normal cells that retain functional checkpoint pathways. Recent evidence also links ATR inhibition to modulation of nuclear cGAS-dependent genome surveillance mechanisms, further amplifying DNA damage in cancer cells (related article).

Mechanism of Action of VE-822 ATR inhibitor

VE-822 is a close analog of VE-821 but exhibits markedly increased potency against ATR kinase (IC₅₀ = 0.019 μM). VE-822 binds and inhibits ATR, blocking downstream phosphorylation of key effectors such as CHK1 (product page). This prevents activation of cell cycle checkpoints, reduces homologous recombination repair of DSBs, and increases persistent DNA lesions. In PDAC cells with dysfunctional p53 and K-Ras, these effects are amplified, resulting in selective radiosensitization and chemosensitization. In vivo, VE-822 enhances the efficacy of radiation and gemcitabine without increasing normal tissue toxicity (Zhen et al., 2023). VE-822’s impact on nuclear cGAS also links ATR signaling to innate immune responses and retrotransposition control, broadening its mechanistic scope (see contrast).

Evidence & Benchmarks

• VE-822 inhibits ATR kinase with an IC₅₀ of 0.019 μM (enzyme assay, DMSO, 25°C) (APExBIO).
• VE-822 sensitizes p53- and K-Ras-mutant PDAC cells to radiation and gemcitabine, increasing tumor growth delay in xenograft models without raising normal tissue toxicity (in vivo, mouse, 2 Gy irradiation + gemcitabine, VE-822 60 mg/kg, oral) (DOI).
• VE-822 reduces homologous recombination repair efficiency, evidenced by decreased RAD51 foci formation after DNA damage (cell-based assay, 37°C, 4 h post-irradiation) (Zhen et al., 2023).
• VE-822 increases persistent γ-H2AX foci in irradiated cancer cells, indicating sustained DNA double-strand break signaling (immunofluorescence, 24 h post-treatment) (DOI).
• VE-822 exhibits high solubility in DMSO (≥50 mg/mL, 25°C), but is insoluble in water or ethanol (solubility assay, APExBIO technical data).

This article updates and extends findings from "VE-822 ATR Inhibitor: Redefining Precision in Pancreatic ..." by providing strict quantitative benchmarks and more detailed mechanistic context for cGAS-related DDR effects.

Applications, Limits & Misconceptions

VE-822 is primarily used as a selective ATR kinase inhibitor for cancer research, with a focus on DDR modulation and radiosensitization of PDAC cells. Its selective action makes it a valuable tool for dissecting ATR signaling, chemoradiotherapy sensitization, and genome integrity pathways. VE-822 is intended strictly for laboratory research use; it is not approved for clinical or diagnostic applications.

Common Pitfalls or Misconceptions

• VE-822 is not effective in tumors with intact p53, where DNA damage checkpoints remain functional and ATR dependence is reduced.
• It is not soluble in water or ethanol; attempts to dissolve it in these solvents result in precipitation and loss of activity.
• Use beyond the recommended storage conditions (stock at -20°C, minimize freeze-thaw cycles) leads to degradation and loss of potency.
• VE-822 does not inhibit ATM or DNA-PK at concentrations selective for ATR, and cannot substitute for pan-PIKK inhibitors.
• VE-822 is not suitable for in vivo use in humans; it is strictly for preclinical research.

For scenario-driven practical guidance on avoiding these and other pitfalls, see "VE-822 ATR Inhibitor (SKU B1383): Scenario-Based Guidance...", which this article complements by providing molecular and benchmark context.

Workflow Integration & Parameters

For optimal results, VE-822 should be dissolved in DMSO (≥50 mg/mL) with gentle warming (37°C) and ultrasonic agitation as needed (product specification). Stock solutions must be stored at -20°C and used promptly. Typical in vitro concentrations range from 10 nM to 1 μM, with exposure times from 1 to 24 hours depending on assay requirements. In vivo, dosing regimens (e.g., 60 mg/kg, oral) should be adapted to experimental models. VE-822 is shipped on blue ice for stability.

For deeper mechanistic protocol integration, see "Reengineering DNA Damage Response: Strategic Pathways for...". This article advances the translational and protocol-focused discussion by providing specific solubility and storage parameters for VE-822.

Conclusion & Outlook

VE-822 ATR inhibitor (SKU B1383, APExBIO) is a validated, potent, and selective tool for dissecting the ATR signaling pathway and DDR in PDAC and related cancer models. Its dual impact on DNA repair and genome integrity positions it as a benchmark compound for preclinical radiosensitization and chemopotentiation studies. Ongoing research continues to explore VE-822’s intersection with cGAS-mediated nuclear surveillance and genome stability mechanisms, expanding its relevance in next-generation cancer biology and therapy development.